Document and Entity Information - USD ($) $ in Millions |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2025 |
Mar. 16, 2026 |
Jun. 30, 2025 |
|
| Cover [Abstract] | |||
| Document Type | 10-K | ||
| Amendment Flag | false | ||
| Document Period End Date | Dec. 31, 2025 | ||
| Document Fiscal Year Focus | 2025 | ||
| Document Fiscal Period Focus | FY | ||
| Trading Symbol | STRO | ||
| Entity Registrant Name | SUTRO BIOPHARMA, INC. | ||
| Entity Central Index Key | 0001382101 | ||
| Current Fiscal Year End Date | --12-31 | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Voluntary Filers | No | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | false | ||
| ICFR Auditor Attestation Flag | false | ||
| Document Financial Statement Error Correction [Flag] | false | ||
| Entity Shell Company | false | ||
| Entity File Number | 001-38662 | ||
| Entity Tax Identification Number | 47-0926186 | ||
| Entity Address, Address Line One | 111 Oyster Point Blvd | ||
| Entity Address, City or Town | South San Francisco | ||
| Entity Address, State or Province | CA | ||
| Entity Address, Postal Zip Code | 94080 | ||
| City Area Code | 650 | ||
| Local Phone Number | 881-6500 | ||
| Entity Common Stock, Shares Outstanding | 16,567,238 | ||
| Security Exchange Name | NASDAQ | ||
| Title of 12(b) Security | Common stock, $0.001 par value | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| Entity Incorporation, State or Country Code | DE | ||
| Entity Interactive Data Current | Yes | ||
| Entity Public Float | $ 60.0 | ||
| Documents Incorporated by Reference | Portions of the registrant’s definitive proxy statement to be filed for its 2026 Annual Meeting of Stockholders are incorporated by reference into Part III hereof. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K. |
||
| Auditor Firm ID | 42 | ||
| Auditor Name | Ernst & Young LLP | ||
| Auditor Location | San Mateo, California | ||
| Auditor Opinion | Opinion on the Financial Statements We have audited the accompanying balance sheets of Sutro Biopharma, Inc. (the Company) as of December 31, 2025 and 2024, the related statements of operations, comprehensive loss, stockholders’ equity (deficit) and cash flows for each of the two years in the period ended December 31, 2025, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025, in conformity with U.S. generally accepted accounting principles. |